SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Payments to Acquire Marketable Securities
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Payments to Acquire Marketable Securities of $43.59 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-31
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2024-09-30 was $7.61K, a 11.69% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2024-06-30 was $17.28K, a 0.47% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments to acquire marketable securities for the quarter ending 2024-03-31 was $18.70K, a 99.37% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments to acquire marketable securities for fiscal 2024 was $43.59K, a 98.55% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments to acquire marketable securities for fiscal 2023 was $3.00M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $7.61K derived: sum of 2 quarters · filed 2026-03-31 | $24.88K derived: sum of 3 quarters · filed 2026-03-31 | $43.59K 10-K · filed 2026-03-31 |
| 2024-09-30 | $7.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $24.88K derived: sum of 2 quarters · filed 2025-11-13 | $43.59K 10-Q · filed 2025-11-13 | $64.44K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $17.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $35.98K 10-Q · filed 2025-08-13 | $56.84K derived: sum of 3 quarters · filed 2025-08-13 | $63.65K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $18.70K 10-Q · filed 2025-05-08 | $39.56K derived: sum of 2 quarters · filed 2025-05-08 | $46.37K derived: sum of 3 quarters · filed 2025-05-08 | $63.57K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $20.86K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $27.67K derived: sum of 2 quarters · filed 2025-02-26 | $44.86K derived: sum of 3 quarters · filed 2025-02-26 | $3.00M 10-K · filed 2025-02-26 |
| 2023-09-30 | $6.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $24.00K derived: sum of 2 quarters · filed 2024-11-13 | $2.98M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $17.20K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $2.97M 10-Q · filed 2024-09-04 | ||
| 2023-03-31 | $2.95M 10-Q/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |